4-氯 -6,7-二甲氧基喹啉 | 35654-56-9

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯 -6,7-二甲氧基喹啉
• 中文别名: 4-氯-6,7-二甲氧基喹啉；4-氯-6,7-二氧基甲基喹啉
• 英文名称: 6,7-dimethoxy-4-chloroquinoline
• 英文别名: 4-chloro-6,7-dimethoxyquinoline
• CAS: 35654-56-9
• 化学式: C₁₁H₁₀ClNO₂
• mdl: MFCD07778437
• 分子量: 223.659
• InChiKey: WRVHQEYBCDPZEU-UHFFFAOYSA-N

物化性质

• 熔点：
  132.0 to 136.0 °C
• 沸点：
  325.2±37.0 °C(Predicted)
• 密度：
  1.265±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  T
• 安全说明：
  S24/25,S45
• 危险类别码：
  R25
• 海关编码：
  29334900
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存放于室温、干燥且密封的环境中。

SDS

4-Chloro-6,7-dimethoxyquinoline
SAFETY DATA SHEET

---

Section 1. IDENTIFICATION
Product name: 4-Chloro-6,7-dimethoxyquinoline
5.3

---

Section 2. HAZARDS IDENTIFICATION
GHS classification
PHYSICAL HAZARDS Not classified
HEALTH HAZARDS
Skin corrosion/irritation Category 2
Category 2A
Serious eye damage/eye irritation
ENVIRONMENTAL HAZARDS Not classified
GHS label elements, including precautionary statements
Pictograms or hazard symbols
Signal word Warning
Hazard statements Causes skin irritation
Causes serious eye irritation
Precautionary statements:
Wash hands thoroughly after handling.
[Prevention]
Wear protective gloves/eye protection/face protection.
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses,
[Response]
if present and easy to do. Continue rinsing.
If eye irritation persists: Get medical advice/attention.
IF ON SKIN: Gently wash with plenty of soap and water.
If skin irritation occurs: Get medical advice/attention.
Take off contaminated clothing and wash before reuse.

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance/mixture: Substance
Components: 4-Chloro-6,7-dimethoxyquinoline
Percent: >98.0%(GC)
CAS Number: 35654-56-9
Chemical Formula: C11H10ClNO2

---

Section 4. FIRST AID MEASURES
Inhalation: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
Get medical advice/attention if you feel unwell.
4-Chloro-6,7-dimethoxyquinoline

---

Section 4. FIRST AID MEASURES
Skin contact: Remove/Take off immediately all contaminated clothing. Gently wash with plenty of
soap and water. If skin irritation or rash occurs: Get medical advice/attention.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing. If eye irritation persists: Get medical
advice/attention.
Ingestion: Get medical advice/attention if you feel unwell. Rinse mouth.
A rescuer should wear personal protective equipment, such as rubber gloves and air-
Protection of first-aiders:
tight goggles.

---

Section 5. FIRE-FIGHTING MEASURES
Suitable extinguishing Dry chemical, foam, water spray, carbon dioxide.
media:
Specific hazards arising Take care as it may decompose upon combustion or in high temperatures to
from the chemical: generate poisonous fume.
Precautions for firefighters: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
method according to the surrounding situation is used. Uninvolved persons should
evacuate to a safe place. In case of fire in the surroundings: Remove movable
containers if safe to do so.
Special protective When extinguishing fire, be sure to wear personal protective equipment.
equipment for firefighters:

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, Use personal protective equipment. Keep people away from and upwind of spill/leak.
protective equipment and Entry to non-involved personnel should be controlled around the leakage area by
emergency procedures: roping off, etc.
Environmental precautions: Prevent product from entering drains.
Methods and materials for Sweep dust to collect it into an airtight container, taking care not to disperse it.
containment and cleaning Adhered or collected material should be promptly disposed of, in accordance with
up: appropriate laws and regulations.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Technical measures: Handling is performed in a well ventilated place. Wear suitable protective equipment.
Prevent dispersion of dust. Wash hands and face thoroughly after handling.
Use a local exhaust if dust or aerosol will be generated.
Advice on safe handling: Avoid contact with skin, eyes and clothing.
Conditions for safe storage, including any
incompatibilities
Storage conditions: Keep container tightly closed. Store in a cool and dark place.
Store away from incompatible materials such as oxidizing agents.
Packaging material: Comply with laws.

---

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Engineering controls: Install a closed system or local exhaust as possible so that workers should not be
exposed directly. Also install safety shower and eye bath.
Personal protective equipment
Respiratory protection: Dust respirator. Follow local and national regulations.
Hand protection: Protective gloves.
Safety glasses. A face-shield, if the situation requires.
Eye protection:
Skin and body protection: Protective clothing. Protective boots, if the situation requires.

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state (20°C): Solid
Crystal- Powder
Form:
Colour: Very pale yellow - Pale yellow
No data available
Odour:
4-Chloro-6,7-dimethoxyquinoline

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
pH: No data available
Melting point/freezing point:134°C
Boiling point/range: No data available
Flash point: No data available
Flammability or explosive
limits:
Lower: No data available
Upper: No data available
Relative density: No data available
Solubility(ies):
[Water] No data available
[Other solvents] No data available

---

Section 10. STABILITY AND REACTIVITY
Chemical stability: Stable under proper conditions.
Possibility of hazardous No special reactivity has been reported.
reactions:
Incompatible materials: Oxidizing agents
Hazardous decomposition Carbon monoxide, Carbon dioxide, Nitrogen oxides (NOx), Hydrogen chloride
products:

---

Section 11. TOXICOLOGICAL INFORMATION
Acute Toxicity: No data available
Skin corrosion/irritation: No data available
Serious eye No data available
damage/irritation:
Germ cell mutagenicity: No data available
Carcinogenicity:
No data available
IARC =
NTP = No data available
Reproductive toxicity: No data available

---

Section 12. ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: No data available
Crustacea: No data available
Algae: No data available
Persistence / degradability: No data available
Bioaccumulative No data available
potential(BCF):
Mobility in soil
Log Pow: No data available
Soil adsorption (Koc): No data available
Henry's Law No data available
constant(PaM3/mol):

---

Section 13. DISPOSAL CONSIDERATIONS
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system.
Observe all federal, state and local regulations when disposing of the substance.

---

Section 14. TRANSPORT INFORMATION
Hazards Class: Does not correspond to the classification standard of the United Nations
UN-No: Not listed
4-Chloro-6,7-dimethoxyquinoline

---

Section 15. REGULATORY INFORMATION
Safe management ordinance of dangerous chemical product (State Council announces on January 26, 2002
and revised on February 16,2011): Safe use and production, the storage of a dangerous chemical, transport,
loading and unloading were prescribed.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

4-氯-6,7-二甲氧基喹啉可用作医药合成中间体，可用于制备如6,7-二甲氧基-4-(哌嗪-1-基)喹啉等中间体。它可以通过以下步骤由6,7-二甲氧基-4-羟基喹啉为原料，在三氯氧磷的作用下反应制备。

制备

4-氯-6,7-二甲氧基喹啉的制备过程如下：

称取2.0g（9.76mmol）6,7-二甲氧基-4-羟基喹啉，溶于20mL三氯氧磷中，回流5小时后减压蒸馏至溶液体积约5mL左右。然后，在外部冰水浴条件下分批倾入30mL冰水中，并同时剧烈搅拌。使用3M NaOH溶液将溶液pH值调至8～9，此时会有大量固体析出。过滤后用10mL×2的水洗涤滤饼，干燥后得到土黄色固体4-氯-6,7-二甲氧基喹啉1.8g，收率83.3%。

用途

4-氯-6,7-二甲氧基喹啉可作为合成各种药物和生物活性化合物的中间体。它被用于制备如蒂沃扎尼（T447205）和卡博替尼（C051500），这两种药物均为抗癌药物。

反应信息

• 作为反应物：
  描述：

  4-氯 -6,7-二甲氧基喹啉 在 potassium tert-butylate 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基乙酰胺 、 水 为溶剂， 反应 9.0h， 生成 卡博替尼
  参考文献：
  名称：

  卡博替尼的新合成

  摘要：

  卡博替尼（1，方案 1）作为 CometriqR 销售，是酪氨酸激酶 c-Met 和 VEGFR2 的小分子抑制剂。它由 Exelixis Inc. 开发，并于 2012 年被美国 FDA 批准用于先前接受过抗血管生成治疗的甲状腺髓样癌和晚期肾细胞癌。迄今为止，已经开发了两种卡博替尼的合成路线。关于关键中间体6,7-二甲氧基喹啉-4-醇(6)的制备，有两种途径，如Scheme 1所示。制备6的常用途径是基于Gould-Jacobs方法，其中Meldrum的酸衍生物4与Dowtherm A在> 230°C下加热数小时得到6。该方法很短，但主要问题是反应温度高导致过程复杂和乏味。Dowtherm A 是一种高沸点溶剂，难以回收，对环境有害，并可能引起工人过敏反应，我们在自己的经验中已经看到了这种影响。或者，1-(2-氨基苯基)ethan-1-one 5 在强碱性条件下与甲酸乙酯反应，以 55%

  DOI：

  10.1080/00304948.2019.1615362
• 作为产物：
  描述：

  3,4-二甲氧基苯胺 在 sodium hydroxide 、 三氯氧磷 作用下， 以 甲醇 、 二苯醚 为溶剂， 反应 4.5h， 生成 4-氯 -6,7-二甲氧基喹啉
  参考文献：
  名称：

  鉴定PDGF受体自身磷酸化的有效和选择性抑制剂。

  摘要：

  我们报告了喹啉和喹唑啉衍生物的结构活性关系，其中包括尿素，硫脲，氨基甲酸酯和酰基硫脲基团，作为血小板衍生生长因子（PDGF）受体自身磷酸化的抑制剂。我们以前的研究表明，包括尿素，硫脲和氨基甲酸酯基团在内的喹啉和喹唑啉衍生物是作为PDGF受体自磷酸化抑制剂的高效化合物，但这些化合物在PDGF受体和c-kit受体之间没有受体选择性。作为进一步合成和生物学评估的结果，我们发现喹啉和喹唑啉-酰基硫脲衍生物不仅显示出对PDGF受体的良好抑制活性，而且还显示了PDGF受体与c-kit受体之间的受体选择性。此外，N- {4-[（6，7-二甲氧基-4-喹啉基）氧基]苯基} -N'-（2-甲基苯甲酰基）硫脲在使用大鼠颈动脉球囊损伤模型的体内试验中显示出有效的口服功效。因此，可以预期喹啉和喹唑啉-酰基硫脲衍生物具有作为治疗再狭窄的治疗剂的潜力。

  DOI：

  10.1021/jm0506423
• 作为试剂：
  描述：

  4-氯 -6,7-二甲氧基喹啉 、 1-((4-hydroxyphenyl)carbamoyl)cyclopropanecarboxylic acid ethyl ester 在 4-氯 -6,7-二甲氧基喹啉 作用下， 以37.8的产率得到1-((4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)carbamoyl)cyclopropanecarboxylic acid ethyl ester
  参考文献：
  名称：

  一种酪氨酸激酶抑制剂及其中间体的制备方法

  摘要：

  本发明涉及一种酪氨酸激酶抑制剂及其中间体的制备方法。本发明的方法是以化合物1，1-环丙烷二羧酸二酯为原料，通过两种途径制备得1-((4-((6，7-二甲氧基喹啉-4-基)氧基)苯基)氨甲酰基)环丙烷甲酸酯；经水解后，与对氟苯胺反应，制备得Cabozantinib。本发明涉及的制备方法反应条件温和，操作简便，降低了合成成本，适合工业化生产。

  公开号：

  CN103664776A

文献信息

• 一类新型的FLT3激酶抑制剂及其用途
  申请人：合肥中科普瑞昇生物医药科技有限公司

  公开号：CN106543143B

  公开（公告）日：2019-03-22

  本发明提供了一种新型激酶抑制剂，其包括式(I)的化合物或其药学可接受的盐、溶剂化物、异构体、酯、酸、代谢物、或前药。本发明还提供包括式(I)化合物的药物组合物及其用于预防或治疗细胞增殖性病症和/或FLT3、c‑Kit相关病症的用途和方法，以及响应于FLT3激酶(尤其是FLT3/ITD突变型激酶)抑制的病症。
• Substituted anilino-quinazoline (or quinoline) compounds and use thereof
  申请人：Astrazeneca AB

  公开号：US06593333B1

  公开（公告）日：2003-07-15

  The invention concerns amide derivatives of Formula (I), wherein: G is N or CH; R1 is a group such as hydroxy, halo, trifluoromethyl, C1-6alkyl and C1-6alkoxy; each of R2 and R3 is hydrogen, halo, C1-6alkyl, C2-6alkenyl or C2-6alkynyl; R4 is a group such as hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy and C3-7cycloalkyl, or R4 is of the Formula (IC): —K—J, wherein J is aryl, heteroaryl or heterocyclyl and K is a bond or a group such as oxy and imino, R5 is a group such as hydrogen, halo and trifluoromethyl: m is 1-3 and q is 0-4; or pharmaceutically acceptable salts or in vivo cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

  该发明涉及式（I）的酰胺衍生物，其中：G为N或CH；R1为羟基、卤素、三氟甲基、C1-6烷基和C1-6烷氧基等基团；R2和R3中的每一个为氢、卤素、C1-6烷基、C2-6烯基或C2-6炔基；R4为氢、羟基、C1-6烷基、C1-6烷氧基和C3-7环烷基等基团，或R4为式（IC）中的基团：—K—J，其中J为芳基、杂芳基或杂环烷基，K为键或氧基、亚胺基等基团；R5为氢、卤素和三氟甲基等基团；m为1-3，q为0-4；或其药学上可接受的盐或体内可水解酯；其制备方法，含有它们的药物组合物以及它们在治疗由细胞因子介导的疾病或医疗状况中的用途。
• Quinoline derivatives inhibiting the effect of growth factors such as VEGF
  申请人：Zeneca Limited

  公开号：US06809097B1

  公开（公告）日：2004-10-26

  Compounds of the formula (I): wherein: R2 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; n is an integer from 0 to 5; Z represents —O—, —NH—, —S— or —CH2—; G1 represents phenyl or a 5-10 membered heteroaromatic cyclic or bicyclic group; Y1, Y2, Y3 and Y4 each independently represents carbon or nitrogen; R1 represents fluoro or hydrogen; m is an integer from 1 to 3; R3 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, —NR4R5 (wherein R4 and R5, can each be hydrogen or C1-3alkyl), or a group R6—X1— wherein X1 represents —CH2— or a heteroatom linker group and R6 is an alkyl, alkenyl or alkynyl chain optionally substituted by for example hydroxy, amino, nitro, alkyl, cycloalkyl, alkoxyalkyl, or an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring, which alkyl, alkenyl or alkynyl chain may have a heteroatom linker group, or R6 is an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans, processes for the preparation of such derivatives, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  公式(I)的化合物： 其中：R2代表羟基，卤素，C1-3烷基，C1-3烷氧基，C1-3烷酰氧基，三氟甲基，氰基，氨基或硝基；n是0到5之间的整数；Z代表—O—，—NH—，—S—或—CH2—；G1代表苯基或一个5-10员的杂芳环状或双环状基团；Y1、Y2、Y3和Y4各自独立代表碳或氮；R1代表氟或氢；m是1到3之间的整数；R3代表氢，羟基，卤素，氰基，硝基，三氟甲基，C1-3烷基，—NR4R5（其中R4和R5各自可以是氢或C1-3烷基），或一个R6—X1—基团，其中X1代表— —或一个杂原子连接基团，R6是一个烷基、烯基或炔基链，该链可选地被例如羟基、氨基、硝基、烷基、环烷基、烷氧基烷基或一个可选地被取代的吡啶酮、苯基和杂环环取代，该烷基、烯基或炔基链可能含有一个杂原子连接基团，或者R6是一个可选地被取代的吡啶酮、苯基和杂环环，以及它们的盐，用于制造一种药物，用于在温血动物如人类中产生抗血管生成和/或降低血管通透性的效果，制备这类衍生物的过程，包含公式I的化合物或其药物可接受的盐作为活性成分的药物组合物，以及公式I的化合物。公式I的化合物及其药物可接受的盐抑制VEGF的效果，这一特性在治疗包括癌症和类风湿性关节炎在内的多种疾病状态中具有价值。
• [EN] FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES FUSIONNÉS ET LEUR UTILISATION
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009136663A1

  公开（公告）日：2009-11-12

  The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

  本发明提供了一种具有强烈激酶抑制活性的融合杂环衍生物及其用途。本发明涉及本说明书中所定义的符号表示的化合物，或其盐。
• Metal-Free Direct C-H β-Carbonyl Alkylation of Heteroarenes with Cyclopropanols Mediated by K₂ S₂ O₈
  作者：Qiang Liu、Qiang Wang、Guanqun Xie、Zeyang Fang、Shujiang Ding、Xiaoxia Wang

  DOI：10.1002/ejoc.202000289

  日期：2020.5.10

  direct C–H β‐carbonyl alkylation of heteroarenes has been achieved through K2S2O8‐mediated ring‐opening of cyclopropanols. A wide scope of substrates, such as various substituted quinolines and isoquinolines, pyridines, pyridazine, benzo[d]thiazole, and phenanthroline, underwent the β‐carbonyl alkylation efficiently and afforded the β‐heteroarylated ketones in moderate to excellent yields.

  无金属直接C-H β羰基杂芳烃烷基化已到K达到2小号2 ö 8介导的cyclopropanols的开环。各种各样的底物，例如各种取代的喹啉和异喹啉，吡啶，哒嗪，苯并[d]噻唑和菲咯啉，有效地进行了β羰基烷基化反应，并以中等至优异的产率提供了β杂芳基化的酮。